78 related articles for article (PubMed ID: 15312353)
1. [Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Wang T; Jiang ZF; Song ST; Zhang SH; Shen G; Yu JX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):379-81. PubMed ID: 15312353
[TBL] [Abstract][Full Text] [Related]
2. [Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer].
Liu X; Song S; Guan Z; Wu S; Duan Y; Yu J; Yang L
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):71-3. PubMed ID: 11977645
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Shiiki S; Sonoo H; Seki M; Nomura T; Hironou M; Ookubo S; Udagawa K; Yamamoto Y; Nakashima K; Ikeda M; Tanaka K; Kurebayashi J
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1431-5. PubMed ID: 17033232
[TBL] [Abstract][Full Text] [Related]
4. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
[TBL] [Abstract][Full Text] [Related]
6. A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
Saeki T; Kimura T; Toi M; Taguchi T
Breast Cancer; 2006; 13(1):49-57. PubMed ID: 16518062
[TBL] [Abstract][Full Text] [Related]
7. [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
Guan ZZ; Liu DG; Yu BM; Wu WQ; Shi D; Zhao Y; Wei YQ; Zou LQ; Wu XD; Zhuang W; Feng FY; Zhang P; Yu SY; Xiong HH; Fu Q; Zheng S; Huang JJ; Wu G; Yang CY; Sun SR; Ruan QL
Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):119-21. PubMed ID: 15059335
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Amari M; Ishida T; Takeda M; Ohuchi N
Jpn J Clin Oncol; 2010 Mar; 40(3):188-93. PubMed ID: 19887522
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
11. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
El-Helw L; Coleman RE
Breast; 2005 Oct; 14(5):368-74. PubMed ID: 16216738
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Chua D; Wei WI; Sham JS; Au GK
Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
[TBL] [Abstract][Full Text] [Related]
16. A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Hyodo I; Shirao K; Doi T; Hatake K; Arai Y; Yamaguchi K; Tamura T; Takemiya S; Takiuchi H; Nakagawa K; Mishima H
Jpn J Clin Oncol; 2006 Jul; 36(7):410-7. PubMed ID: 16825251
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
18. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
19. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
